ArticleScience advances2023
Immune engineered extracellular vesicles to modulate T cell activation in the context of type 1 diabetes.
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Review
- Evaluating Variability in Extracellular Vesicle Characterization Across Measurement Techniques.Journal of extracellular biology · 2026Article
- Unlocking beta cell health: The clinical potential of extracellular vesicles in type 1 diabetes.Clinical and translational medicine · 2026Review
- Extracellular vesicle-mediated immune-metabolic crosstalk: research advances in inflammatory regulation and the pathogenesis of metabolic diseases.Frontiers in immunology · 2026Review
- Extracellular vesicles at the immune-metabolic crossroads of Hashimoto's thyroiditis and diabetes mellitus.Frontiers in immunology · 2026Review
- Recruiting ESCRT to single-chain heterotrimer peptide MHCI releases antigen-presenting vesicles that stimulate T cells selectively.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Engineering HLA-G-targeted extracellular vesicles nanoplatform for enhanced cancer therapy through precise cancer drug delivery.Nature communications · 2025Article
- Induction of antigen-specific regulatory T cells by engineered extracellular vesicles.Drug delivery · 2025Article
- Exosomes in review: A new frontier in CAR-T cell therapies.Neoplasia (New York, N.Y.) · 2025Review
- Direct delivery of immune modulators to tumour-infiltrating lymphocytes using engineered extracellular vesicles.Journal of extracellular vesicles · 2025Article
- Unlocking Transplant Tolerance with Biomaterials.Advanced healthcare materials · 2025Review
- Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8Diabetologia · 2025Article
- Identification of crucial extracellular genes as potential biomarkers in newly diagnosed Type 1 diabetesPeerJ · 2025Article
- Review
- Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders.Signal transduction and targeted therapy · 2024Review
- Granular Hydrogels for Harnessing the Immune Response.Advanced healthcare materials · 2024Review
- High throughput and rapid isolation of extracellular vesicles and exosomes with purity using size exclusion liquid chromatography.Bioactive materials · 2024Article
- Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of Type 1 Diabetes.bioRxiv : the preprint server for biology · 2024Article
- Engineering antigen-presenting cells for immunotherapy of autoimmunity.Advanced drug delivery reviews · 2024Review
- Optical Imaging of Single Extracellular Vesicles: Recent Progress and Prospects.Chemical & biomedical imaging · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Extracellular vesicles (EVs) can affect immune responses through antigen presentation and costimulation or coinhibition. We generated designer EVs to modulate T cells in the context of type 1 diabetes, a T cell-mediated autoimmune disease, by engineering a lymphoblast cell line, K562, to express HLA-A*02 (HLA-A2) alongside costimulatory CD80 and/or coinhibitory programmed death ligand 1 (PD-L1). EVs presenting HLA-A2 and CD80 activated CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.